Compare $AKTX vs $KPTI | Chartloom

Compare

$AKTX vs $KPTI

Akari Therapeutics PLC · Karyopharm Therapeutics Inc

AKTX

Akari Therapeutics PLC

KPTI

Karyopharm Therapeutics Inc

Compare $AKTX vs $KPTI

Comparing Akari Therapeutics PLC and Karyopharm Therapeutics Inc

AKTXAkari Therapeutics PLC

KPTIKaryopharm Therapeutics Inc

AKTXAkari Therapeutics PLC

Market cap

$17M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-24.4%

52W performance

-78.5%

FCF yield

-63.0%

KPTIKaryopharm Therapeutics Inc

Market cap

$14M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.10x

Rev growth (TTM)

6.8%

YTD performance

-91.6%

52W performance

-89.7%

FCF yield

-476.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AKTX

KPTI

Detailed metrics comparison

AKTX

Akari Therapeutics PLC

KPTI

Karyopharm Therapeutics Inc

Market Cap

AKTX$17M

KPTI$14M

Enterprise Value

AKTX$10M

KPTI$281M

Price

AKTX$8.77

KPTI$0.61

P/E Ratio

AKTXN/A

KPTIN/A

P/S Ratio

AKTX0.00x

KPTI0.09x

EV/Sales

AKTX0.00x

KPTI1.92x

EV/EBITDA

AKTX0.00x

KPTI0.00x

P/B Ratio

AKTX0.83x

KPTI0.36x

P/FCF Ratio

AKTXN/A

KPTIN/A

EV/FCF

AKTX-0.94x

KPTI-4.30x

PEG Ratio

AKTXN/A

KPTIN/A

Forward P/E (NTM)

AKTXN/A

KPTIN/A

Forward P/S (NTM)

AKTXN/A

KPTI0.10x

Revenue (TTM)

AKTX$0

KPTI$147M

Revenue Growth (YoY)

AKTXN/A

KPTI6.8%

Forward Rev Growth

AKTX137.9%

KPTI27.7%

Gross Margin (TTM)

AKTX0.0%

KPTI95.9%

Operating Margin (TTM)

AKTX0.0%

KPTI0.0%

EBITDA Margin (TTM)

AKTX0.0%

KPTI-56.1%

Net Margin (TTM)

AKTX0.0%

KPTI-153.3%

FCF Margin (TTM)

AKTXN/A

KPTI-44.6%

Net Income (TTM)

AKTX$-31M

KPTI$-225M

FCF (TTM)

AKTX$-11M

KPTI$-65M

EPS (TTM)

AKTX-$0.40

KPTI-$7.77

ROE (TTM)

AKTX-14745.0%

KPTI-18243.0%

ROA (TTM)

AKTX-7470.0%

KPTI-20094.0%

ROIC (TTM)

AKTX-14027.0%

KPTI-6632.0%

Cash

AKTX$8M

KPTI$55M

Debt

AKTX$693K

KPTI$322M

Net Cash/Debt

AKTX$7M

KPTI$-267M

Current Ratio (TTM)

AKTX0.60x

KPTI0.79x

Quick Ratio (TTM)

AKTX0.56x

KPTI0.71x

Debt/Equity (TTM)

AKTX0.04x

KPTI3.78x

Debt/Assets (TTM)

AKTX0.0%

KPTI0.0%

Interest Coverage (TTM)

AKTXN/A

KPTIN/A

Net Debt/EBITDA (TTM)

AKTX0.00x

KPTI0.00x

Beta

AKTX1.48

KPTI1.14

52W Performance

AKTX-78.5%

KPTI-89.7%

YTD Performance

AKTX-24.4%

KPTI-91.6%

% from 52W High

AKTX-79.5%

KPTI-94.5%

% from 52W Low

AKTX190.4%

KPTI7.1%

Asset Turnover (TTM)

AKTX0.00x

KPTI1.31x

FCF Yield (TTM)

AKTX-63.0%

KPTI-476.7%

Earnings Yield (TTM)

AKTX-181.3%

KPTI-1639.3%

Dividend Yield (TTM)

AKTXN/A

KPTIN/A

Rule of 40

AKTX0.0

KPTI-37.8

EV/GP/RG

AKTXN/A

KPTI0.07

Ticker research

View AKTX research View KPTI research

Metric	AKTX Akari Therapeutics PLC	KPTI Karyopharm Therapeutics Inc
Market & Valuation
Market Cap	$17M	$14M
Enterprise Value	$10M	$281M
Price	$8.77	$0.61
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.09x
EV/Sales	0.00x	1.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.83x	0.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.94x	-4.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.10x
Revenue & Growth
Revenue (TTM)	$0	$147M
Revenue Growth (YoY)	N/A	6.8%
Forward Rev Growth	137.9%	27.7%
Profitability
Gross Margin (TTM)	0.0%	95.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-56.1%
Net Margin (TTM)	0.0%	-153.3%
FCF Margin (TTM)	N/A	-44.6%
Net Income (TTM)	$-31M	$-225M
FCF (TTM)	$-11M	$-65M
EPS (TTM)	-$0.40	-$7.77
ROE (TTM)	-14745.0%	-18243.0%
ROA (TTM)	-7470.0%	-20094.0%
ROIC (TTM)	-14027.0%	-6632.0%
Financial Health
Cash	$8M	$55M
Debt	$693K	$322M
Net Cash/Debt	$7M	$-267M
Current Ratio (TTM)	0.60x	0.79x
Quick Ratio (TTM)	0.56x	0.71x
Debt/Equity (TTM)	0.04x	3.78x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.48	1.14
52W Performance	-78.5%	-89.7%
YTD Performance	-24.4%	-91.6%
% from 52W High	-79.5%	-94.5%
% from 52W Low	190.4%	7.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.31x
FCF Yield (TTM)	-63.0%	-476.7%
Earnings Yield (TTM)	-181.3%	-1639.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-37.8
EV/GP/RG	N/A	0.07
Ticker research	View AKTX research	View KPTI research

Valuation

P/S Ratio

AKTX

0.00x

KPTI

0.09x

EV/FCF

KPTI

-4.30x

AKTX

-0.94x

Growth & revenue

Revenue Growth TTM

KPTI

6.8%

Forward Revenue Growth

AKTX

137.9%

KPTI

27.7%

Profitability & performance

Gross Margin

KPTI

95.9%

AKTX

0.0%

ROE

AKTX

-14745.0%

KPTI

-18243.0%

FCF Yield %

AKTX

-63.0%

KPTI

-476.7%

52-Week Performance

AKTX

-78.5%

KPTI

-89.7%

Detailed metrics comparison

AKTX

Akari Therapeutics PLC

KPTI

Karyopharm Therapeutics Inc

Market Cap

AKTX$17M

KPTI$14M

Enterprise Value

AKTX$10M

KPTI$281M

Price

AKTX$8.77

KPTI$0.61

P/E Ratio

AKTXN/A

KPTIN/A

P/S Ratio

AKTX0.00x

KPTI0.09x

EV/Sales

AKTX0.00x

KPTI1.92x

EV/EBITDA

AKTX0.00x

KPTI0.00x

P/B Ratio

AKTX0.83x

KPTI0.36x

P/FCF Ratio

AKTXN/A

KPTIN/A

EV/FCF

AKTX-0.94x

KPTI-4.30x

PEG Ratio

AKTXN/A

KPTIN/A

Forward P/E (NTM)

AKTXN/A

KPTIN/A

Forward P/S (NTM)

AKTXN/A

KPTI0.10x

Revenue (TTM)

AKTX$0

KPTI$147M

Revenue Growth (YoY)

AKTXN/A

KPTI6.8%

Forward Rev Growth

AKTX137.9%

KPTI27.7%

Gross Margin (TTM)

AKTX0.0%

KPTI95.9%

Operating Margin (TTM)

AKTX0.0%

KPTI0.0%

EBITDA Margin (TTM)

AKTX0.0%

KPTI-56.1%

Net Margin (TTM)

AKTX0.0%

KPTI-153.3%

FCF Margin (TTM)

AKTXN/A

KPTI-44.6%

Net Income (TTM)

AKTX$-31M

KPTI$-225M

FCF (TTM)

AKTX$-11M

KPTI$-65M

EPS (TTM)

AKTX-$0.40

KPTI-$7.77

ROE (TTM)

AKTX-14745.0%

KPTI-18243.0%

ROA (TTM)

AKTX-7470.0%

KPTI-20094.0%

ROIC (TTM)

AKTX-14027.0%

KPTI-6632.0%

Cash

AKTX$8M

KPTI$55M

Debt

AKTX$693K

KPTI$322M

Net Cash/Debt

AKTX$7M

KPTI$-267M

Current Ratio (TTM)

AKTX0.60x

KPTI0.79x

Quick Ratio (TTM)

AKTX0.56x

KPTI0.71x

Debt/Equity (TTM)

AKTX0.04x

KPTI3.78x

Debt/Assets (TTM)

AKTX0.0%

KPTI0.0%

Interest Coverage (TTM)

AKTXN/A

KPTIN/A

Net Debt/EBITDA (TTM)

AKTX0.00x

KPTI0.00x

Beta

AKTX1.48

KPTI1.14

52W Performance

AKTX-78.5%

KPTI-89.7%

YTD Performance

AKTX-24.4%

KPTI-91.6%

% from 52W High

AKTX-79.5%

KPTI-94.5%

% from 52W Low

AKTX190.4%

KPTI7.1%

Asset Turnover (TTM)

AKTX0.00x

KPTI1.31x

FCF Yield (TTM)

AKTX-63.0%

KPTI-476.7%

Earnings Yield (TTM)

AKTX-181.3%

KPTI-1639.3%

Dividend Yield (TTM)

AKTXN/A

KPTIN/A

Rule of 40

AKTX0.0

KPTI-37.8

EV/GP/RG

AKTXN/A

KPTI0.07

Ticker research

View AKTX research View KPTI research

Metric	AKTX Akari Therapeutics PLC	KPTI Karyopharm Therapeutics Inc
Market & Valuation
Market Cap	$17M	$14M
Enterprise Value	$10M	$281M
Price	$8.77	$0.61
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.09x
EV/Sales	0.00x	1.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.83x	0.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.94x	-4.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.10x
Revenue & Growth
Revenue (TTM)	$0	$147M
Revenue Growth (YoY)	N/A	6.8%
Forward Rev Growth	137.9%	27.7%
Profitability
Gross Margin (TTM)	0.0%	95.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-56.1%
Net Margin (TTM)	0.0%	-153.3%
FCF Margin (TTM)	N/A	-44.6%
Net Income (TTM)	$-31M	$-225M
FCF (TTM)	$-11M	$-65M
EPS (TTM)	-$0.40	-$7.77
ROE (TTM)	-14745.0%	-18243.0%
ROA (TTM)	-7470.0%	-20094.0%
ROIC (TTM)	-14027.0%	-6632.0%
Financial Health
Cash	$8M	$55M
Debt	$693K	$322M
Net Cash/Debt	$7M	$-267M
Current Ratio (TTM)	0.60x	0.79x
Quick Ratio (TTM)	0.56x	0.71x
Debt/Equity (TTM)	0.04x	3.78x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.48	1.14
52W Performance	-78.5%	-89.7%
YTD Performance	-24.4%	-91.6%
% from 52W High	-79.5%	-94.5%
% from 52W Low	190.4%	7.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.31x
FCF Yield (TTM)	-63.0%	-476.7%
Earnings Yield (TTM)	-181.3%	-1639.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-37.8
EV/GP/RG	N/A	0.07
Ticker research	View AKTX research	View KPTI research